Author:
Hayes Wesley,Bockenhauer Detlef
Publisher
Springer International Publishing
Reference35 articles.
1. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847–58.
2. Arima H, Cheetham T, Christ-Crain M, Cooper D, Drummond J, Gurnell M, Levy M, McCormack A, Newell-Price J, Verbalis JG, Wass J. Working group for renaming diabetes insipidus. J Clin Endocrinol Metab. 2022;108(1):1–3. https://doi.org/10.1210/clinem/dgac547.
3. Baumer JH, Coulthard M, Haycock G, McIntosh N, Rammal R, Haines L. The differential diagnosis of hypernatremia in children with particular reference to salt poisoning. An evidence-based guideline. London: RCPCH; 2009.
4. Bichet DG, Bockenhauer D. Genetic forms of nephrogenic diabetes insipidus (NDI): vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant). Best Pract Res Clin Endocrinol Metab. 2016;30(2):263–76.
5. Bichet DG, Razi M, Lonergan M, Arthus MF, Papukna V, Kortas C, Barjon JN. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med. 1988;318(14):881–7.